Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity

被引:57
|
作者
Zafrani, L. [1 ,2 ]
Mariotte, E. [1 ,2 ]
Darmon, M. [3 ,4 ]
Canet, E. [1 ,2 ]
Merceron, S. [1 ,2 ]
Boutboul, D. [2 ,5 ]
Veyradier, A. [6 ]
Galicier, L. [2 ,5 ]
Azoulay, E. [1 ,2 ]
机构
[1] Hop St Louis, AP HP, Med Intens Care Unit, Paris, France
[2] Paris Diderot Univ, Paris, France
[3] St Etienne Univ Hosp, Med Surg Intens Care Unit, St Etienne, France
[4] Univ St Etienne, St Etienne, France
[5] Hop St Louis, AP HP, Dept Clin Immunol, Paris, France
[6] Antoine Beclere Hosp, Dept Hematol, Clamart, France
关键词
acute kidney injury; ADAMTS13; protein; human; complement system proteins; renal replacement therapy; thrombotic thrombocytopenic purpura; VON-WILLEBRAND-FACTOR; HEMOLYTIC-UREMIC SYNDROME; FACTOR-CLEAVING PROTEASE; ACUTE KIDNEY INJURY; COMPLEMENT ACTIVATION; ORGAN DYSFUNCTION; DEFICIENCY; MICROANGIOPATHIES; DEFINITION; EXPERIENCE;
D O I
10.1111/jth.12826
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundAmong patients with thrombotic microangiopathies, acute kidney injury (AKI) is the hallmark of hemolytic uremic syndrome (HUS) and is largely underestimated in patients with thrombotic thrombocytopenic purpura (TTP). ObjectiveWe sought to report AKI features and outcomes in patients with TTP. MethodsWe conducted a retrospective study of 92 patients with TTP assessed by low ADAMTS13 activity (<10%) between 2001 and 2013. A logistic regression identified variables independently associated with AKI. ResultsAmong the 92 patients, 54 (58.7%) presented with AKI, including 25 (46.3%) with stage 3 AKI. Fourteen (27.4%) patients had a nephrotic-range proteinuria and 21 (45.6%) had hemoglobinuria. Hematuria and leucocyturia were detected in 19 (41.3%) and 16 patients (36.4%), respectively. Renal replacement therapy (RRT) was required in 14 patients (25.9%). Six months after TTP remission, RRT-free patients had median (IQR) MDRD (Modification of Diet in Renal Disease formula estimating the glomerular filtration rate) of 93mLmin(-1) per 1.73m(2) (68.8-110) and three patients required long-term dialysis. Mild or moderate chronic renal disease occurred in 23/54 (42.6%) AKI patients. By multivariate analysis, serum level of complement component 3 at admission was the only factor independently associated with AKI (OR per 0.25 unit decrease of C3, 0.85; CI, 1.82-8.33; P=0.001). ConclusionsIn patients with TTP, AKI is present in more than half the patients, and half of those will have lasting renal effects. Further studies to better understand the pathophysiology of renal involvement in patients with TTP and to identify a subset of patients with TTP syndrome overlapping HUS are warranted.
引用
收藏
页码:380 / 389
页数:10
相关论文
共 50 条
  • [1] News in thrombotic thrombocytopenic purpura and ADAMTS13
    Joly, Berangere
    Beranger, Nicolas
    Benhamou, Ygal
    Coppo, Paul
    Veyradier, Agnes
    HEMATOLOGIE, 2021, 27 (04): : 188 - 199
  • [2] Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura
    Shin, Yongchol
    Miyake, Haruki
    Togashi, Kenshi
    Hiratsuka, Ryuichi
    Endou-Ohnishi, Kana
    Imamura, Yasutada
    JOURNAL OF BIOCHEMISTRY, 2018, 163 (05) : 381 - 389
  • [3] Diagnosis and follow-up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay
    Beranger, Nicolas
    Benghezal, Sandrine
    Joly, Berangere S.
    Capdenat, Sophie
    Delton, Adeline
    Stepanian, Alain
    Coppo, Paul
    Veyradier, Agnes
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2021, 5 (01) : 81 - 93
  • [4] The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura
    Lotta, Luca A.
    Wu, Haifeng M.
    Musallam, Khaled M.
    Peyvandi, Flora
    BLOOD REVIEWS, 2013, 27 (02) : 71 - 76
  • [5] Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura
    Zheng, X. Long
    Wu, Haifeng M.
    Shang, Dezhi
    Falls, Erica
    Skipwith, Christopher G.
    Cataland, Spero R.
    Bennett, Charles L.
    Kwaan, Hau C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (09): : 1555 - 1562
  • [6] Thrombotic thrombocytopenic purpura and ADAMTS13
    Kokame, Koichi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2007, 127 : 19 - 20
  • [7] Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura
    Manea, Minola
    Karpman, Diana
    PEDIATRIC NEPHROLOGY, 2009, 24 (03) : 447 - 458
  • [8] Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura
    Han-Mou Tsai
    International Journal of Hematology, 2002, 76 : 132 - 138
  • [9] Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification
    Dimopoulos, Konstantinos
    Philips, Malou
    Goetze, Jens P.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2022, 7 (03) : 637 - 649
  • [10] ADAMTS13 and thrombotic thrombocytopenic purpura Retrospective study at the hospital of Le Mans
    Bovet, Julien
    Pineau-Vincent, Fabienne
    ANNALES DE BIOLOGIE CLINIQUE, 2014, 72 (03) : 321 - 330